Single-Center Analysis of Immunotherapy Combined with Anti-Angiogenics Versus Immuno-therapy Alone for Patients with Advanced Non-Small Cell Lung Cancer
OBJECTIVE:To investigate the clinical value of immunotherapy combined with antiangiogenics compared with immunomonotherapy in the treatment of second-line and above advanced non-small cell lung cancer(NSCLC),so as to find the suitable immunotherapy regimen for second-line and above advanced NSCLC.METHODS:Thirty eight patients with advanced NSCLC received immunomonotherapy or immunotherapy combined with antiangiogenics from Jan.2017 to Nov.2020 were retrospectively analyzed,20 patients were treated with immunomonotherapy(monotherapy group),and 18 patients were treated with immunotherapy combined with antiangiogenics(combined group).Progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR)and adverse drug reactions were observed.RESULTS:The median PFS of monotherapy group and combined group were respectively 4.84 months(95%CI:from 3.50 months to 6.18 months)and 8.13 months(95%CI:from 5.65 months to 10.62 months),the median PFS of combined group was longer than that of monotherapy group,the difference was statistically significant(P=0.009).Compared with monotherapy regimen,PFS in males,patients with smoking,adenocarcinoma,and programmed death receptor ligand 1(PD-L1)expression level≥1%was longer(P<0.05).Multifactor analysis showed that PD-L1 expression level was an independent factor affecting PFS in combination therapy.ORR of patients in the monotherapy group and combined group was respectively 10.00%(2/20)and 27.78%(5/18),and the ORR of the combined group was higher than that in monotherapy group,the difference was not statistically significant(P = 0.158).DCR of patients in monotherapy group and combined group was respectively 65.00%(13/20)and 77.78%(14/18),with no statistically significant difference(P=0.632).Adverse drug reactions were tolerated in both groups,and no adverse drug reactions of grade 3 or above occurred in the combined group.CONCLUSIONS:Immunotherapy combined with antiangiogenics can prolong the PFS of advanced NSCLC patients in second-line and above treatment.PD-L1 expression level is an independent factor affecting PFS in combination therapy,and combination therapy is safe and controllable.
Non-small cell lung cancerImmunotherapyAntiangiogenicsClinical efficacyAdverse drug reactions
万方数据
维普
